Successful Management of Lupus-Associated Autoimmune Myelofibrosis with Tofacitinib: A Case Report

ACR Open Rheumatol. 2025 Mar;7(3):e70017. doi: 10.1002/acr2.70017.

Abstract

We report a case of a 34-year-old woman with systemic lupus erythematosus (SLE) who developed thrombocytopenia and was diagnosed with lupus-associated autoimmune myelofibrosis. She was treated with hydroxychloroquine, tofacitinib (5 mg twice daily), intravenous Ig, and prednisone (5 mg twice daily, tapered to 5 mg daily after one month). After 10 months of this regimen, her bone marrow showed complete resolution of myelofibrosis. This case highlights the effectiveness of tofacitinib in the treatment of autoimmune myelofibrosis associated with SLE.

Publication types

  • Case Reports